Reference health
The Gender-Specific Association of DRD2 Polymorphism with Metabolic Syndrome in Patients with Schizophrenia
65/65 checkable references clean · checked 2026-07-22
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
6 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 65 checked references that resolve
resolves10.4088/JCP.14074su1c.02
Impact of Cognitive and Social Cognitive Impairment on Functional Outcomes in Patients With Schizophrenia
resolves10.1017/S0033291716003366
The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis
resolves10.1002/mpr.240
Meta‐analyses of the incidence and prevalence of schizophrenia: conceptual and methodological issues
resolves10.1093/schbul/sby058
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
resolves10.1192/bjp.bp.110.077289
Treatment adherence therapy in people with psychotic disorders: randomised controlled trial
resolves10.1016/j.pnpbp.2009.01.010
Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia
resolves10.1038/tp.2011.66
NMDA receptor genotypes associated with the vulnerability to develop dyskinesia
resolves10.1177/2050312116643673
Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations
resolves10.3389/fnmol.2020.00063
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia
resolves10.1080/15622975.2018.1548780
Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of<i>CHRM1</i>and<i>CHRM2</i>muscarinic receptors
resolves10.1080/15622975.2016.1224926
Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia
resolves10.1186/s12881-019-0773-3
A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia
resolves10.3390/jpm11030181
Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia
resolves10.1002/wps.20252
Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis
resolves10.31887/DCNS.2018.20.1/bpenninx
Metabolic syndrome in psychiatric patients: overview, mechanisms, and implications
resolves10.3389/fpsyt.2021.661174
Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals
resolves10.1111/obr.12229
Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies
resolves10.1016/S2215-0366(15)00115-7
Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses
resolves10.1016/j.heliyon.2019.e02033
Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia
resolves10.2147/NDT.S247161
<p>Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia</p>
resolves10.3390/diagnostics10090683
Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome
resolves10.3390/ph14050446
Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics
resolves10.1017/neu.2017.8
Circuits regulating pleasure and happiness: evolution and role in mental disorders
resolves10.1016/j.tins.2007.06.004
Is dopamine a physiologically relevant mediator of feeding behavior?
resolves10.1016/j.tics.2010.11.001
Reward, dopamine and the control of food intake: implications for obesity
resolves10.1038/mp.2011.109
Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
resolves10.1093/schbul/sbw058
Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis
resolves10.1371/journal.pone.0215477
Sex differences in gene expression related to antipsychotic induced weight gain
resolves10.1017/neu.2019.41
Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain
resolves10.3389/fphar.2019.01669
Progress in Genetic Polymorphisms Related to Lipid Disturbances Induced by Atypical Antipsychotic Drugs
resolves10.1177/0269881120903462
Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period
resolves10.1177/0706743716644765
Dopamine 2 Receptor Genes Are Associated with Raised Blood Glucose in Schizophrenia
resolves10.1016/j.biopsych.2009.08.040
Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs
resolves10.1097/01.med.0000216967.74622.9c
Obesity, dopamine and the metabolic syndrome: potential of dopaminergic agents in the control of metabolism
resolves10.1093/hmg/6.4.577
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
resolves10.1038/sj.mp.4000532
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers
resolves10.1038/tp.2016.22
Genetic variation and dopamine D2 receptor availability: a systematic review and meta-analysis of human in vivo molecular imaging studies
resolves10.4103/jpp.JPP_197_16
Risperidone-Induced Adverse Drug Reactions and Role of DRD2 (−141 C Ins/Del) and 5HTR2C (−759 C>T) Genetic Polymorphisms in Patients with Schizophrenia
resolves10.1016/j.psyneuen.2016.06.002
Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis
resolves10.1371/journal.pone.0036561
Candidate Gene-Based Association Study of Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients: A Prospective Study
resolves10.3390/biomedicines9080879
Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients
resolves10.1097/FPC.0b013e3282f01aa3
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine
resolves10.1097/FPC.0b013e32833ca24b
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia
resolves10.1007/s40519-020-00851-5
Associations of the ANKK1 and DRD2 gene polymorphisms with overweight, obesity and hedonic hunger among women from the Northwest of Iran
resolves10.1097/FPC.0b013e3283397d06
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment
resolves10.1038/oby.2010.150
BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists
resolves10.1080/17446651.2018.1434412
The effects of hyperprolactinemia and its control on metabolic diseases
resolves10.1038/s41398-020-01171-z
Dopamine regulates pancreatic glucagon and insulin secretion via adrenergic and dopaminergic receptors
resolves10.1523/JNEUROSCI.23-15-06245.2003
Receptor Subtypes Involved in the Presynaptic and Postsynaptic Actions of Dopamine on Striatal Interneurons
resolves10.1016/j.tins.2007.03.001
Dopamine-mediated regulation of corticostriatal synaptic plasticity
resolves10.1016/j.neuropharm.2010.01.008
Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum
The 6 references without a DOI — listed, not checked
no DOI — not checkedCognitive deficit in schizophrenia: An overview
no DOI — not checkedSearch for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients
no DOI — not checkedSystematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain
no DOI — not checkedAssociation between polymorphisms of LEP, LEPR, DRD2, HTR2A and HTR2C genes and risperidone- or clozapine-induced hyperglycemia
no DOI — not checkedWorld Health Organization (2004). International Statistical Classification of Diseases and Health Related Problems ICD-10, World Health Organization.
no DOI — not checkedThe dopamine D2 receptor 5′-flanking variant, -141C Ins/Del, is not associated with reduced dopamine D2 receptor density in vivo
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-22 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.3390/genes13081312"><img src="https://citestamp.com/citestamped/10.3390/genes13081312/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.3390/genes13081312)